These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8937467)

  • 1. Improvement of metabolic disorders and visceral fat obesity by the beta 3-adrenoceptor agonist (R*,R*)-(+/-)-methyl-4-[2-[2-hydroxy-2 -(3-chlorophenyl)ethylamino]propyl]-phenoxyacetate hydrobromide (BRL35135A) in genetically obese rodents.
    Hashimoto K; Nagao Y; Ida K; Takeda M; Murakami N; Kato K; Mizota M
    Biochem Pharmacol; 1996 Nov; 52(10):1529-35. PubMed ID: 8937467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereoselective action of (R*,R*)-(+/-)-methyl-4-[2-[2-hydroxy-2-(3-chlorophenyl)ethylamino] propyl]-phenoxyacetic acid (BRL37344) on beta-adrenoceptors and metabolic chiral inversion.
    Ida K; Hashimoto K; Kamiya M; Muto S; Nakamura Y; Kato K; Mizota M
    Biochem Pharmacol; 1996 Nov; 52(10):1521-7. PubMed ID: 8937466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of the anti-obesity effect of the selective beta 3-adrenoceptor agonist BRL 35135 in obese Zucker rats by exercise.
    Santti E; Huupponen R; Rouru J; Hänninen V; Pesonen U; Jhanwar-Uniyal M; Koulu M
    Br J Pharmacol; 1994 Dec; 113(4):1231-6. PubMed ID: 7889277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta3-adrenoceptors mediate relaxation of guinea pig taenia caecum by BRL37344A and BRL35135A.
    Koike K; Takayanagi I; Ichino T; Koshikawa H; Nagatomo T
    Eur J Pharmacol; 1997 Sep; 334(2-3):217-21. PubMed ID: 9369351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic treatment with BRL 35135 potentiates the action of insulin on lipid metabolism.
    Virtanen KA; Rouru J; Hänninen V; Savontaus E; Rouvari T; Teirmaa T; Koulu M; Huupponen R
    Eur J Pharmacol; 1997 Aug; 332(2):215-8. PubMed ID: 9286624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of novel beta-adrenoceptor agonists on carbohydrate metabolism: relevance for the treatment of non-insulin-dependent diabetes.
    Cawthorne MA; Carroll MJ; Levy AL; Lister CA; Sennitt MV; Smith SA; Young P
    Int J Obes; 1984; 8 Suppl 1():93-102. PubMed ID: 6152558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term and rapid regulation of ob mRNA levels in adipose tissue from normal (Sprague Dawley rats) and obese (db/db mice, fa/fa rats) rodents.
    Igel M; Kainulainen H; Brauers A; Becker W; Herberg L; Joost HG
    Diabetologia; 1996 Jul; 39(7):758-65. PubMed ID: 8817099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential regulation of uncoupling proteins by chronic treatments with beta 3-adrenergic agonist BRL 35135 and metformin in obese fa/fa Zucker rats.
    Savontaus E; Rouru J; Boss O; Huupponen R; Koulu M
    Biochem Biophys Res Commun; 1998 May; 246(3):899-904. PubMed ID: 9618309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a beta 3-adrenergic agonist, BRL35135A, on glucose uptake in rat skeletal muscle in vivo and in vitro.
    Abe H; Minokoshi Y; Shimazu T
    J Endocrinol; 1993 Dec; 139(3):479-86. PubMed ID: 7907647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diazoxide enhances basal metabolic rate and fat oxidation in obese Zucker rats.
    Alemzadeh R; Karlstad MD; Tushaus K; Buchholz M
    Metabolism; 2008 Nov; 57(11):1597-607. PubMed ID: 18940400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic administration of BRL 26830A for 9 weeks improves insulin sensitivity but does not prevent weight gain in gold-thioglucose obese mice.
    Bryson JM; Wensley VR; Phuyal JL; Caterson ID; Cooney GJ
    Horm Metab Res; 1999 May; 31(5):317-22. PubMed ID: 10422727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Appearance of brown adipocytes in white adipose tissue during CL 316,243-induced reversal of obesity and diabetes in Zucker fa/fa rats.
    Ghorbani M; Himms-Hagen J
    Int J Obes Relat Metab Disord; 1997 Jun; 21(6):465-75. PubMed ID: 9192230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRL 35135, a potent and selective atypical beta-adrenoceptor agonist.
    Cawthorne MA; Sennitt MV; Arch JR; Smith SA
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):252S-257S. PubMed ID: 1345889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors.
    Carpéné C; Abello V; Iffiú-Soltész Z; Mercier N; Fève B; Valet P
    Pharmacol Res; 2008 Jun; 57(6):426-34. PubMed ID: 18539478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CL-316,243, a beta3-specific adrenoceptor agonist, enhances insulin-stimulated glucose disposal in nonobese rats.
    de Souza CJ; Hirshman MF; Horton ES
    Diabetes; 1997 Aug; 46(8):1257-63. PubMed ID: 9231648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance.
    de Souza CJ; Eckhardt M; Gagen K; Dong M; Chen W; Laurent D; Burkey BF
    Diabetes; 2001 Aug; 50(8):1863-71. PubMed ID: 11473050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute injection of beta-adrenoceptor agonist BRL 35135 corrects both impaired uncoupling protein and lipoprotein lipase gene expression but not hypercapacity of lipogenesis in brown adipose tissue of suckling fa/fa rats.
    Marie V; Dupuy F; Bazin R
    Int J Obes Relat Metab Disord; 1994 May; 18(5):273-9. PubMed ID: 7914794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amelioration of insulin resistance in genetically obese rodents by M16209, a new antidiabetic agent.
    Murakami N; Ohta M; Hashimoto K; Kato K; Mizota M; Miwa I; Okuda J; Inoue G; Kuzuya H; Nakao K; Imura H
    Eur J Pharmacol; 1996 May; 304(1-3):129-34. PubMed ID: 8813594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats.
    Picard F; Deshaies Y; Lalonde J; Samson P; Richard D
    Obes Res; 2000 Dec; 8(9):656-63. PubMed ID: 11225714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with CL 316,243, a beta 3-adrenoceptor agonist, reduces serum leptin in rats with diet- or aging-associated obesity, but not in Zucker rats with genetic (fa/fa) obesity.
    Ghorbani M; Himms-Hagen J
    Int J Obes Relat Metab Disord; 1998 Jan; 22(1):63-5. PubMed ID: 9481601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.